209 related articles for article (PubMed ID: 22001634)
21. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
22. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
23. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
24. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
25. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
Kalady MF; Sanchez JA; Manilich E; Hammel J; Casey G; Church JM
Dis Colon Rectum; 2009 Jun; 52(6):1039-45. PubMed ID: 19581844
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma.
Shinjo K; Okamoto Y; An B; Yokoyama T; Takeuchi I; Fujii M; Osada H; Usami N; Hasegawa Y; Ito H; Hida T; Fujimoto N; Kishimoto T; Sekido Y; Kondo Y
Carcinogenesis; 2012 Jul; 33(7):1277-85. PubMed ID: 22532250
[TBL] [Abstract][Full Text] [Related]
27. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.
Ang PW; Li WQ; Soong R; Iacopetta B
Cancer Lett; 2009 Jan; 273(2):221-4. PubMed ID: 18778891
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between CpG island methylator phenotype and genetic instability in sporadic colorectal cancer].
Cai GX; Xu Y; Cai SJ; Shi YQ; Lian P; Peng JJ; Guan ZQ; Du X
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Nov; 10(6):555-60. PubMed ID: 18000779
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
31. Accumulation of DNA methylation is associated with tumor stage in gastric cancer.
Oue N; Mitani Y; Motoshita J; Matsumura S; Yoshida K; Kuniyasu H; Nakayama H; Yasui W
Cancer; 2006 Mar; 106(6):1250-9. PubMed ID: 16475210
[TBL] [Abstract][Full Text] [Related]
32. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
[TBL] [Abstract][Full Text] [Related]
33. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
34. Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma.
Cheng Y; Zhang C; Zhao J; Wang C; Xu Y; Han Z; Jiang G; Guo X; Li R; Bu X; Wu M; Wei L
Exp Mol Pathol; 2010 Feb; 88(1):112-7. PubMed ID: 19879258
[TBL] [Abstract][Full Text] [Related]
35. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype.
Nosho K; Kawasaki T; Chan AT; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Histopathology; 2008 Nov; 53(5):588-98. PubMed ID: 18983468
[TBL] [Abstract][Full Text] [Related]
36. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.
Messick CA; Church JM; Liu X; Ting AH; Kalady MF
Ann Surg Oncol; 2010 Feb; 17(2):425-31. PubMed ID: 19885699
[TBL] [Abstract][Full Text] [Related]
37. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
[TBL] [Abstract][Full Text] [Related]
38. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
[TBL] [Abstract][Full Text] [Related]
39. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
[TBL] [Abstract][Full Text] [Related]
40. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Laskar RS; Ghosh SK; Talukdar FR
Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
